cell lines skmel28 Search Results


skmel28 cell line  (Array BioPharma)
90
Array BioPharma skmel28 cell line
(A) Experimental setup for cell line xenograft studies of mice + binimetinib or encorafinib. X-axis describes days of therapy and drug treatment (M=MEKi, binimetinib and B=BRAFi, encorafinib). (B) Volcano plot, average fold change in pMHC expression with binimetinib treatment (n=3 biological replicates for DMSO and MEKi treated cells) versus significance (mean-adjusted p value, unpaired two-sided t test) for <t>IPC298</t> CLX. (C) Violin plot of distribution of fold changes in presentation of pMHCs following MEK inhibition (M, binimetinib), BRAF inhibition (B, encorafinib) or both (B/M). Solid line represents median, dotted lines define the first and third quartiles. (D) TAA enrichment significance values for each analysis. Black dotted line represents p≥0.05, grey = p≥0.01. (E) Changes in pMHC expression for select melanoma differentiation antigens. Errors bars represent standard deviation when >1 peptide from each source protein was identified.
Skmel28 Cell Line, supplied by Array BioPharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/skmel28 cell line/product/Array BioPharma
Average 90 stars, based on 1 article reviews
skmel28 cell line - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

Image Search Results


(A) Experimental setup for cell line xenograft studies of mice + binimetinib or encorafinib. X-axis describes days of therapy and drug treatment (M=MEKi, binimetinib and B=BRAFi, encorafinib). (B) Volcano plot, average fold change in pMHC expression with binimetinib treatment (n=3 biological replicates for DMSO and MEKi treated cells) versus significance (mean-adjusted p value, unpaired two-sided t test) for IPC298 CLX. (C) Violin plot of distribution of fold changes in presentation of pMHCs following MEK inhibition (M, binimetinib), BRAF inhibition (B, encorafinib) or both (B/M). Solid line represents median, dotted lines define the first and third quartiles. (D) TAA enrichment significance values for each analysis. Black dotted line represents p≥0.05, grey = p≥0.01. (E) Changes in pMHC expression for select melanoma differentiation antigens. Errors bars represent standard deviation when >1 peptide from each source protein was identified.

Journal: bioRxiv

Article Title: MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas

doi: 10.1101/2022.01.10.475285

Figure Lengend Snippet: (A) Experimental setup for cell line xenograft studies of mice + binimetinib or encorafinib. X-axis describes days of therapy and drug treatment (M=MEKi, binimetinib and B=BRAFi, encorafinib). (B) Volcano plot, average fold change in pMHC expression with binimetinib treatment (n=3 biological replicates for DMSO and MEKi treated cells) versus significance (mean-adjusted p value, unpaired two-sided t test) for IPC298 CLX. (C) Violin plot of distribution of fold changes in presentation of pMHCs following MEK inhibition (M, binimetinib), BRAF inhibition (B, encorafinib) or both (B/M). Solid line represents median, dotted lines define the first and third quartiles. (D) TAA enrichment significance values for each analysis. Black dotted line represents p≥0.05, grey = p≥0.01. (E) Changes in pMHC expression for select melanoma differentiation antigens. Errors bars represent standard deviation when >1 peptide from each source protein was identified.

Article Snippet: SKMEL5, SKMEL28, SKMEL2, and IPC298 cell lines were used for cell line xenograft (CLX) analyses in collaboration with Array Biopharma.

Techniques: Expressing, Inhibition, Standard Deviation